DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

March 31, 2018

Conditions
Acute Non-ST Elevation Myocardial Infarction
Interventions
DRUG

DLBS1033

Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks

DRUG

Placebo

Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks

Trial Locations (2)

13570

Binawaluya Cardiac Hospital, Jakarta

Unknown

Central Army Hospital RSPAD Gatot Soebroto, Central Jakarta

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dexa Medica Group

INDUSTRY

NCT02146664 - DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization | Biotech Hunter | Biotech Hunter